在线观看视频你懂的,久久久精品人妻一区二区三区gv,五级黄高潮片90分钟视频

Pfizer Secures Global Rights to SSGJ-707: A Next-Gen PD-1/VEGF Bispecific for Cancer Treatment Pfizer Pfizer acquires global rights to SSGJ-707, a PD-1/VEGF bispecific antibody from 3SBio, aiming to enhance its oncology pipeline with a novel mechanism and strong clinical potential.
Zai Lab Breakthrough at ASCO: DLL3 ADC and TTFields Pancreatic Cancer Advances ASCO Discover how biotech leader Zai Lab is making waves at ASCO with groundbreaking DLL3 ADC clinical data and innovative TTFields therapy expanding into pancreatic cancer, driving strong growth and strategic transformation.
ASCO 2025: Opening a New Era of "Cancer Eradication" ASCO Discover the latest breakthroughs from ASCO 2025, including innovative cancer treatments, immunotherapy advances, bispecific antibodies, and promising breast cancer therapies shaping the future of oncology.
ASCO 2025: AstraZeneca's Breakthrough Innovations in Cancer Treatment Leading Global Oncology Advances ASCO Discover AstraZeneca’s groundbreaking cancer research at ASCO 2025, featuring innovative therapies in breast, lung, and digestive cancers. Leading global oncology with advanced treatments and strategic local-global integration.
ASCO 2025: BMS Defends Opdualag's Future After Adjuvant Melanoma Setback BMS Bristol Myers Squibb’s Opdualag failed to improve outcomes in adjuvant melanoma, raising questions about LAG-3 antibodies. Despite this, BMS remains confident in ongoing NSCLC trials targeting PD-1 positive patients.
Bicara and Merus Compete in HNSCC Drug Development Race ASCO Bicara and Merus are advancing competing therapies for head and neck cancer (HNSCC). While Merus shows strong early OS data, Bicara focuses on long-term outcomes, especially in HPV-negative patients, with a pivotal trial underway.
Proposed NIH Cancer Research Cuts Spark Industry Concern ASCO The Trump administration’s proposed budget cuts to NIH and NCI risk hindering cancer research progress, prompting strong opposition from ASCO and ACS CAN over potential impacts on patient outcomes and innovation.
Kura and Kyowa's Ziftomenib Shows 23% Remission in AML Trial ASCO Kura Oncology and Kyowa Kirin announced a 23% remission rate in their phase 2 trial of oral leukemia drug ziftomenib for relapsed/refractory NPM1-mutant AML, with FDA approval under review and phase 3 trials planned.
ASCO 2025: 14 Chinese ADC Therapies Showcase Strong Efficacy Across Multiple Tumors ASCO At ASCO 2025, 14 Chinese ADC therapies demonstrated impressive efficacy and safety across various cancers, including breast, lung, gastric, and urothelial, signaling strong global potential for domestically developed treatments.
IBI-363 Shines at ASCO 2025: Innovent’s Breakthrough Immunotherapy Shows Game-Changing Results ASCO Discover how Innovent's IBI-363 made a groundbreaking impact at ASCO 2025 with impressive efficacy in NSCLC, melanoma, and colorectal cancer. A potential game-changer in next-gen immunotherapy.

<Pre12 3 Next >

Articles Archives

Hot Articles

All Categories

Agri & Industry Cosmetic Laboratory Pharmaceutical Food

永久免费毛片_亚洲成人看片_亚洲春色另类_亚洲综合免费视频_最新高清无码专区_午夜影院a